Australia Markets closed

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.85+0.24 (+3.15%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.61
Open7.58
Bid0.00 x 2200
Ask0.00 x 800
Day's range7.39 - 8.29
52-week range6.15 - 12.05
Volume9,776
Avg. volume14,508
Market cap65.606M
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Lumos Pharma to Participate in Upcoming Investor Conferences

    AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event:H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26thPresentation:Live presentation May 25th at 4:00 – 4:30 PM EDTWebcast link:Here Event:Jefferies Healthcare Conference – June 8th – 10thPresentation: Live fireside chat

  • GlobeNewswire

    Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

    --Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration Initiated with Massachusetts General Hospital for Evaluation of LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in Phase 2 Pilot Trial-- AUSTIN, Texas, May 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stag

  • GlobeNewswire

    Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

    The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDAAUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (G